The PIPE included common stock and pre-funded warrants

Davis Polk advised the placement agents in connection with GRAIL, Inc.’s $325 million private placement of common stock and pre-funded warrants.

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies and state-of-the-art machine learning, software and automation to detect and identify multiple deadly cancer types in earlier stages.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Sunny Xu and Robb Dehney. Partner Frank Azzopardi and associates Shreya R. Kundur and Nazli Ungan provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post